FPA157 / Amgen, BMS - LARVOL DELTA

Five Prime Presents First Preclinical Data on Anti-CCR8 Antibody FPA157 (Businesswire) - "Preclinical data support evaluation of FPA157 as a novel immunomodulator with the potential to remove Treg-mediated immune suppression in solid tumors; FPA157 is an anti-CCR8 antibody engineered to enhance antibody-dependent cell-mediated cytotoxicity to preferentially eliminate CCR8+ Treg cells in the tumor microenvironment; Data presented today at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) show investigational immunotherapy FPA157 elicits anti-tumor activity in multiple preclinical models."

Preclinical • Oncology • Solid Tumor

[VIRTUAL] Development of FPA157, an anti-CCR8 depleting antibody engineered to preferentially eliminate tumor-infiltrating T regulatory cells (SITC 2020) - "Conclusions FPA157 is a CCR8-specific monoclonal antibody with eADCC activity that is being developed for the treatment of cancer. Depletion of CCR8+ Tregs induced substantial anti-tumor activity in pre-clinical models, thus supporting the clinical evaluation of FPA157 as a novel approach to alleviate immune suppression in the microenvironment of human solid tumors."

IO Biomarker • Late-breaking abstract • Oncology • Solid Tumor • CD8 • FOXP3

[VIRTUAL] Development of FPA157, an anti-CCR8 depleting antibody engineered to preferentially eliminate tumor-infiltrating T regulatory cells (SITC 2020) - "Conclusions FPA157 is a CCR8-specific monoclonal antibody with eADCC activity that is being developed for the treatment of cancer. Depletion of CCR8+ Tregs induced substantial anti-tumor activity in pre-clinical models, thus supporting the clinical evaluation of FPA157 as a novel approach to alleviate immune suppression in the microenvironment of human solid tumors."

IO Biomarker • Late-breaking abstract • Oncology • Solid Tumor • CD8 • FOXP3

Five Prime Therapeutics Reports Third Quarter 2020 Results (Businesswire) - "The company expects to report top-line data before year end from the double-blind Phase 2 FIGHT study where all 155 patients receive standard mFOLFOX6 chemotherapy and are randomized to receive bemarituzumab or placebo....The company’s FPA157 late-breaking abstract has been accepted for a poster presentation at the 2020 Society of Immunotherapy of Cancer (SITC) Annual Meeting. The company expects to submit an IND application for this program in the first half of 2022."

IND • P2 data • Preclinical • Gastric Cancer • Gastrointestinal Cancer • Oncology

Five Prime to Present First Preclinical Data of Anti-CCR8 Antibody FPA157 at Society for Immunotherapy of Cancer Virtual Annual Meeting (Businesswire) - "Five Prime Therapeutics...announced the upcoming virtual poster presentation of the first preclinical data from its anti-CCR8 antibody, FPA157 program, at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting being held from November 9-14, 2020...Data will be presented during the late-breaker virtual poster sessions on November 11 and November 13, 2020."

Preclinical • Oncology